Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ImmuStem
- Development stage
- Preclinical
- Lead developer
- Escape Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
ImmuStem is a preclinical-stage cell therapy being developed by Escape Therapeutics for the treatment of graft-versus-host disease (GVHD). The therapy utilizes immune-tolerant mesenchymal stromal/stem cells (MSCs) derived from adult sources. The mechanism of action involves using these stem cells to modulate immune responses, with the goal of preventing or treating GVHD, a serious complication that can occur following allogeneic hematopoietic stem cell transplantation. As a cell-based therapeutic modality, ImmuStem represents an approach to address GVHD through immune regulation rather than traditional pharmacological immunosuppression.
- Brand names
- ImmuStem
Beyond the preview
Go deeper on ImmuStem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmuStem.